Research Library
BPC-157 research
6 articles to explore, with links to 8 original sources.
About BPC-157
BPC-157 is a synthetic, fifteen-residue peptide used to investigate cellular signaling and peptide stability.
Understand the science
How scientists tracked the intact peptide in animals
BPC-157 is a synthetic 15-amino-acid peptide. In an older 2022 study, researchers examined how long the intact molecule remained in animal blood and what happened to its components as it was processed. The investigators measured BPC-157 in rats and beagle dogs.
1 source (2022)
How two rat tendon studies used different injury models
BPC-157 is a synthetic 15-amino-acid peptide studied in tendon injury models. An older experiment tested it after cutting rat Achilles tendons, while a July 2026 study also sutured the cut tendon. Comparing the models shows why details of the injury and repair matter when scientists measure healing.
2 sources (2003, 2026)
Explore study findings
What the October 2026 compounding notice covers
BPC-157 is a synthetic 15-amino-acid peptide investigated in tissue injury models. In October 2026, the U.S. Department of Health and Human Services published a notice about an interim policy on certain peptide bulk drug substances.
2 sources (2026)
What isolated human artery rings can reveal
BPC-157 is a synthetic chain of 15 amino acids being studied in vascular and tissue injury experiments. In May 2026, a laboratory study used pieces of human artery to ask whether BPC-157 affected vessel tension and whether the artery's inner lining contributed to the response.
1 source (2026)
Check methods and identity
What a 2026 rat experiment measured after blood flow returned
BPC-157 is a synthetic peptide containing 15 amino acids. In May 2026, researchers reported an experiment that asked whether it changed early signs of damage when blood flow returned to a rat's hind limb after a temporary interruption.
1 source (2026)
How a registered hamstring study plans to measure recovery
BPC-157 is an experimental 15-amino-acid peptide. A clinical trial registered in February 2026 proposes to study it in people with acute grade II hamstring strains confirmed by magnetic resonance imaging.
1 source (2026)
